September 29, 2019
Clover Biopharmaceuticals doses first patient in phase I study of SCB-313 in China for Malignant Ascites
CHENGDU, China–(BUSINESS WIRE)–Clover Biopharmaceuticals, a biotechnology company focused on developing novel and transformative biologic therapies, today announced that the first…